The lifetime risk of pancreatic cancer in CDKN2A pathogenic variant carriers is high (17–21% at 70–75 years of age [5, 7]), however with this incidence, segregation assays may result in false negative even in prospectively followed cohorts. This evidence concerns the gene CDKN2A and pancreatic neoplasm.